Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Keros Therapeutics (KROS) Other Non Operating Income (2019 - 2025)

Historic Other Non Operating Income for Keros Therapeutics (KROS) over the last 7 years, with Q3 2025 value amounting to -$253000.0.

  • Keros Therapeutics' Other Non Operating Income fell 17500.0% to -$253000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.0 million, marking a year-over-year decrease of 5560.54%. This contributed to the annual value of -$954000.0 for FY2024, which is 36310.68% down from last year.
  • Latest data reveals that Keros Therapeutics reported Other Non Operating Income of -$253000.0 as of Q3 2025, which was down 17500.0% from -$221000.0 recorded in Q2 2025.
  • Keros Therapeutics' Other Non Operating Income's 5-year high stood at $762000.0 during Q3 2022, with a 5-year trough of -$1.4 million in Q4 2022.
  • Moreover, its 5-year median value for Other Non Operating Income was -$101000.0 (2021), whereas its average is -$156210.5.
  • Over the last 5 years, Keros Therapeutics' Other Non Operating Income had its largest YoY gain of 65620.44% in 2022, and its largest YoY loss of 128811.88% in 2022.
  • Over the past 5 years, Keros Therapeutics' Other Non Operating Income (Quarter) stood at -$101000.0 in 2021, then crashed by 1288.12% to -$1.4 million in 2022, then surged by 103.99% to $56000.0 in 2023, then crashed by 508.93% to -$229000.0 in 2024, then dropped by 10.48% to -$253000.0 in 2025.
  • Its Other Non Operating Income stands at -$253000.0 for Q3 2025, versus -$221000.0 for Q2 2025 and -$338000.0 for Q1 2025.